Novo Nordisk to Invest USD 506 Million to Expand Oral GLP-1 Drug Manufacturing in Ireland
Written By : sheeba farhat
Published On 2026-03-03 15:16 GMT | Update On 2026-03-03 15:16 GMT
New Delhi: Novo Nordisk said on Monday it will invest 432 million euros (USD 506.43 million) to expand its manufacturing facility in Athlone, Ireland.
"With the investment in the Athlone facility, Novo Nordisk is expanding its production capacities for oral products, which will strengthen our ability to meet both current and future demand, outside the U.S.," said Novo Nordisk's head of product supply, Kasper Bodker Mejlvang, in a statement.
The investment would improve Novo Nordisk's capacity to manufacture oral versions of its GLP-1 drugs, which include Wegovy and Ozempic, the company added.
The construction projects, which have already begun, will be finalised gradually from the end of 2027 through 2028, Novo said.
Our comments section is governed by our Comments Policy . By posting comments at Medical Dialogues you automatically agree with our Comments Policy , Terms And Conditions and Privacy Policy .
Disclaimer: This website is primarily for healthcare professionals. The content here does not replace medical advice and should not be used as medical, diagnostic, endorsement, treatment, or prescription advice. Medical science evolves rapidly, and we strive to keep our information current. If you find any discrepancies, please contact us at corrections@medicaldialogues.in. Read our Correction Policy here. Nothing here should be used as a substitute for medical advice, diagnosis, or treatment. We do not endorse any healthcare advice that contradicts a physician's guidance. Use of this site is subject to our Terms of Use, Privacy Policy, and Advertisement Policy. For more details, read our Full Disclaimer here.
NOTE: Join us in combating medical misinformation. If you encounter a questionable health, medical, or medical education claim, email us at factcheck@medicaldialogues.in for evaluation.